Data investigation

Does Maryland Medicaid Cover Wegovy or Zepbound? Chapter 866 and the Current Rules

Chapter 866 of 2026 lets Maryland Medicaid cover obesity drugs from January 1, 2027, without requiring it, and no election was announced by November 2026. Until then one form covers Wegovy for heart disease or MASH, plus Zepbound for sleep apnea.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·15 citations

Not for weight loss, as of November 2026. A state regulation bars Maryland Medicaid from paying for drugs “when used for weight control,” so Wegovy and Zepbound are not covered for obesity alone.[1] A 2026 law, Chapter 866, lets the program add obesity drugs from January 1, 2027 but does not require it, and the health department had not announced that it would.[2] Today one state form covers Wegovy for heart disease or the liver disease MASH and Zepbound for sleep apnea, each with prior authorization.[5]

About this article. This page reads the Maryland Department of Health’s Wegovy and Zepbound prior authorization form (December 2025 version), its online clinical criteria (last revised July 2026), its transmittals on both drugs, the fee-for-service drug list updated August 6, 2026, the state regulations and Chapter 866 of 2026, as they stood on November 6, 2026. The state requires HealthChoice managed care plans to use its Wegovy criteria, and for Zepbound it tells prescribers to ask the plan, so check with yours. To compare states, use the state Medicaid GLP-1 checker.

Will Maryland Medicaid pay for Wegovy or Zepbound to lose weight?

No. The pharmacy regulation lists what the program does not cover, and one item is any drug or injection used for weight control.[1] When the state added Wegovy for heart disease in 2024, it said plainly that a prescription written only to manage weight would still be refused.[6] Federal law makes that a state choice. Our explainer on the federal rule behind Medicaid weight-loss exclusions covers it.

What does Maryland’s 2026 obesity law, Chapter 866, change?

It opens a door without pushing anyone through it. Senate Bill 496 became Chapter 866 on May 31, 2026 without the governor’s signature, and took effect October 1, 2026.[2][3] It says that from January 1, 2027 the program “may” provide comprehensive obesity coverage, defined as intensive behavioral therapy, bariatric surgery and any FDA-approved drug for chronic weight management.[2] If the department chooses to, it must tell members, and it may use prior authorization only in the same way it does for other conditions.[2]

Cost is the obstacle. The legislature’s fiscal note put the drug cost alone at as much as $449.4 million a year if the state adopts the benefit, drawing on a 2024 department estimate of $225 million to $437.7 million depending on how many people start treatment.[4] The note also says the department was weighing the federal BALANCE model, under which CMS negotiates GLP-1 prices for state Medicaid programs, but that as of March 2026 the terms had not reached states.[4] The law requires the department to report by November 1, 2027 on whether it has started the coverage and, if not, why.[2] We found no notice electing the coverage as of November 6, 2026.

Maryland obesity drug coverage: what is law and what is not, as of November 6, 2026
ItemStatus
Regulation excluding weight-control drugsIn force
Chapter 866 (SB 496), enacted May 31, 2026In force from October 1, 2026; permits, does not require, obesity coverage
Earliest start of obesity drug coverageJanuary 1, 2027, only if the department elects it
Member notice of the electionNone found
Department report to the legislatureDue by November 1, 2027

When does Maryland Medicaid pay for Wegovy?

For two uses, both on one form from the Office of Pharmacy Services. The form says incomplete requests will not be reviewed, and the prescriber also attests that the patient tried a weight-loss program in the past six months without success.[5] Approval lasts four months at first, then six months at a time.[15] Since July 2026 the state’s criteria also list the Wegovy tablet, for the heart use only, on the same cardiologist and BMI terms and at one tablet a day.[15]

Maryland Medicaid Wegovy criteria, from the MDH prior authorization form (December 2025 version), the state's clinical criteria and the Wegovy label
UseRequirementsPrescriber
Lowering heart attack and stroke riskA past heart attack, a past stroke, or leg artery disease with symptoms (ABI under 0.85 with claudication, a revascularization or an amputation); BMI of 27 or more recorded within 90 days; no other GLP-1A cardiologist, or another doctor in consultation with one
MASH with F2 to F3 fibrosisNoncirrhotic MASH; moderate to advanced fibrosis, as on the label, confirmed by biopsy or an accepted noninvasive test within 180 days; no other GLP-1 and no other MASH drugA gastroenterologist or liver specialist, or in consultation with one

Two points need care. The 2024 notice that opened the heart route limited it to adults without type 1 or type 2 diabetes, and told managed care plans to use the same criteria.[6] Neither the December 2025 form nor the state’s criteria, last revised July 2026, repeats that limit. If a plan cites it, ask for the current criteria; people with diabetes can also use Ozempic on the diabetes route.[5][15][8] And the specialist requirement is real: a request from a primary care doctor needs a cardiologist or liver specialist named as consulting. The liver use carries accelerated approval, pending a confirmatory trial.[12] Our page on semaglutide for MASH covers the evidence for it.

Does Maryland Medicaid cover Zepbound for sleep apnea?

Yes, since February 5, 2025, for adults with obesity, the group the label covers.[7][11] The form asks for a sleep study, in a lab or at home, scoring 15 or more on the apnea-hypopnea index, a BMI from 30 up recorded within 90 days, a sleep specialist, lung doctor or other clinician experienced in sleep apnea, and no second GLP-1.[5] It sets no CPAP step.[5]

Renewal has a twist. Approvals renew six months at a time on the prescriber’s word that the drug is helping, and after a year the sleep apnea has to be documented again each year, by a sleep study or CPAP data.[5][7][15] But the state also says renewals will not be authorized once BMI is under 30.[7] Zepbound lowers weight, so a patient who does well can lose coverage by crossing that line, even with sleep apnea still present. Raise this with the prescriber early. Our guide to Zepbound for obstructive sleep apnea explains what the trials found.

Does Maryland Medicaid cover Ozempic and Mounjaro for diabetes?

Yes. On the fee-for-service drug list updated August 6, 2026, Ozempic, Mounjaro, Trulicity and generic liraglutide (Victoza) are preferred drugs, and Rybelsus and Byetta need prior authorization as non-preferred drugs.[8] The legislature’s fiscal note confirms that the program covers these diabetes drugs for their approved uses other than obesity.[4]

How do you file, and how long does an appeal take?

Fee-for-service requests go to the Office of Pharmacy Services by fax at (866) 440-9345; the phone line is (833) 325-0105.[5] HealthChoice members file through their plan, and the state tells prescribers to contact the plans for their process.[7]

A plan member has 60 days from the plan’s notice to appeal to the plan, and then 120 days from the plan’s decision to ask the Office of Administrative Hearings for a state fair hearing.[9] Plans must offer a faster review when waiting could seriously harm the member’s health.[9] For fee-for-service denials, federal rules cap the hearing window at 90 days from the date the notice is mailed, so use the date on your notice.[10] Our walkthrough of prior authorization and appeals covers what to put in the file, and the Maryland state page keeps the basics together.

What can you do until Maryland adds coverage?

Paying cash is the usual route, and Lilly’s savings card excludes Medicaid members.[13] In the figures we track, Novo Nordisk sells most Wegovy pen doses for $349 a month, and Lilly’s Zepbound KwikPen or vial runs $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time.[13][14] Check each program’s rules for government coverage first. Our list of the lowest GLP-1 prices without insurance compares them.

Frequently Asked Questions

No. A state regulation excludes drugs used for weight control. As of November 2026 Maryland Medicaid covers Wegovy with prior authorization only to lower heart risk in people with a past heart attack or stroke or with leg artery disease, or to treat MASH with F2 to F3 fibrosis, with a specialist involved.
Possibly. Chapter 866 of 2026 allows, but does not require, the program to cover obesity drugs from January 1, 2027. The health department must notify members if it chooses to and report to the legislature by November 1, 2027. No election had been announced as of November 2026.
Yes, for adults with obesity. The request needs a sleep study with an AHI of 15 or more, a BMI from 30 up measured within 90 days, and a sleep specialist or lung doctor. Renewals run six months, and the state stops renewing once BMI falls under 30.
Yes. For the heart route, the state form asks that Wegovy be prescribed by a cardiologist or in consultation with one. For the MASH route, it asks for a gastroenterologist or liver specialist.
Yes, for type 2 diabetes. Both are preferred drugs on the fee-for-service list updated August 6, 2026, along with Trulicity and generic liraglutide.

References

  1. 1.Maryland Department of Health COMAR 10.09.03.05: Pharmacy Services, Limitations Division of State Documents, dsd.maryland.gov. 2026. https://dsd.maryland.gov/regulations/Pages/10.09.03.05.aspx
  2. 2.Maryland General Assembly Chapter 866 of 2026 (Senate Bill 496): Maryland Medical Assistance Program, Coverage for the Treatment of Obesity, Authorization mgaleg.maryland.gov. 2026. https://mgaleg.maryland.gov/2026RS/Chapters_noln/CH_866_sb0496e.pdf
  3. 3.Maryland General Assembly SB 496, 2026 Regular Session: bill status and history mgaleg.maryland.gov. 2026. https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/sb0496?ys=2026RS
  4. 4.Department of Legislative Services Fiscal and Policy Note, Senate Bill 496 (Enrolled, Revised), 2026 Session mgaleg.maryland.gov. 2026. https://mgaleg.maryland.gov/2026RS/fnotes/bil_0006/sb0496.pdf
  5. 5.Maryland Department of Health, Office of Pharmacy Services Wegovy and Zepbound Prior Authorization Form (MDH 12/2025) health.maryland.gov. 2025. https://health.maryland.gov/mmcp/pap/docs/PA%20Forms/Wegovy%20or%20Zepbound%20PA%20form.pdf
  6. 6.Maryland Department of Health PT 35-25: Coverage of Wegovy for Overweight or Obese Adults with Cardiovascular Disease, Effective September 15, 2024 health.maryland.gov. 2024. https://health.maryland.gov/mmcp/provider/Documents/transmittals/PT35-25-Coverage-of-Wegovy-for-Overweight-or-Obese-Adults-with-Cardiovascular-Disease.pdf
  7. 7.Maryland Department of Health PT 74-25: Notice of Zepbound Coverage Effective February 5, 2025 (copy posted by Aetna Better Health of Maryland) aetnabetterhealth.com. 2025. https://es.aetnabetterhealth.com/content/dam/aetna/medicaid/pdfs/formulary/guidelines/PT-74-25-Notice-of-Zepbound-Coverage-ua.pdf
  8. 8.Maryland Department of Health, Office of Pharmacy Services Medicaid Pharmacy Program Preferred Drug List, effective July 1, 2026, updated August 6, 2026 health.maryland.gov. 2026. https://health.maryland.gov/mmcp/pap/docs/PDL-updated-8-6-2026.pdf
  9. 9.Maryland Department of Health COMAR 10.67.09.05: MCO Appeal Process for Enrollees Division of State Documents, dsd.maryland.gov. 2026. https://dsd.maryland.gov/regulations/Pages/10.67.09.05.aspx
  10. 10.Centers for Medicare & Medicaid Services 42 CFR 431.221: Request for hearing eCFR. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-431/subpart-E/section-431.221
  11. 11.Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  12. 12.Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  13. 13.Eli Lilly and Company Zepbound savings and self-pay options, with card terms zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings
  14. 14.Novo Nordisk Wegovy savings offer novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html
  15. 15.Maryland Department of Health, Office of Pharmacy Services Clinical Criteria: Wegovy, Wegovy tablet and Zepbound health.maryland.gov. 2026. https://health.maryland.gov/mmcp/pap/Pages/Clinical-Criteria.aspx

Does Louisiana Medicaid Cover Wegovy or Zepbound? Act 898 and Today's Rules

Louisiana passed Act 898 in June 2026 to make Medicaid pay for weight-loss drugs, but the law waits on an appropriation that neither 2026 budget act contains. Until then: Wegovy for heart risk or MASH, Zepbound for sleep apnea, diabetes drugs, PA lines and appeals.

8 min read

Does Illinois Medicaid Cover Ozempic, Wegovy or Zepbound? Diabetes Yes, Weight Loss No

Illinois Medicaid's October 2026 drug list covers Ozempic for type 2 diabetes, with the tablets preferred over the pen, and opens Wegovy for heart risk and MASH and Zepbound for sleep apnea. Weight loss alone stays excluded. Status by drug, plan criteria and appeals.

7 min read

Does Alaska Medicaid Cover Wegovy or Zepbound? Heart, Liver and Sleep Apnea Rules

Alaska bars Medicaid payment for obesity drugs, yet its September 2026 criteria approve Wegovy after a heart attack, stroke or MASH from a BMI of 25, and Zepbound for sleep apnea from a BMI of 30. The short first approval, the AHI wording and the 30-day appeal clock.

8 min read

Does Washington Apple Health Cover Wegovy or Zepbound? The Three Medical Routes

Washington's Apple Health bars drugs prescribed for weight loss. HCA policies still approve Wegovy for established heart or artery disease or MASH, and Zepbound for sleep apnea without a CPAP trial, for adults without diabetes. Plus the diabetes split, exceptions and appeals.

8 min read

Does TennCare Cover Wegovy and Zepbound? Yes, for Obesity, With a 5% Renewal Test

TennCare has covered obesity drugs since August 2025. Its current criteria make Wegovy and the Zepbound pen preferred, open Wegovy to teens, require 5% weight loss to renew, and send heart, sleep apnea and MASH requests to a separate form with its own tests.

7 min read

Utah Medicaid and Wegovy or Zepbound After the Weight-Loss Pilot Ended

Utah Medicaid paid for Wegovy, Zepbound and Saxenda for obesity under a legislative pilot that its form capped at June 30, 2026. What remains: Wegovy for heart disease or MASH, Zepbound for sleep apnea with PAP, and diabetes GLP-1s that need only a diagnosis code.

7 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

See the Maryland page for the sellers that ship there and other facts about the state.

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →